Literature DB >> 9199905

Vertical lines in distal esophageal mucosa (VLEM): a true endoscopic manifestation of esophagitis in children?

S K Gupta1, J F Fitzgerald, S K Chong, J M Croffie, M H Collins.   

Abstract

BACKGROUND: We observed an endoscopic abnormally in a group of children with histological esophagitis. We termed this finding "vertical lines in esophageal mucosa" (VLEM). We examined the relationship between the presence of VLEM and significant histologic changes in esophageal mucosal biopsies.
METHODS: Between January 1, 1992, and August 31, 1994, the senior author (JFF) performed 255 esophageal biopsies. The procedure reports, available endoscopic photographs, and histology reports were reviewed to establish the endoscopic and histologic appearance of the esophageal mucosa. Intraepithelial cells were counted in a blind review of 42 randomly selected biopsies.
RESULTS: The esophageal mucosa had a normal appearance on 160 endoscopic studies (Group 1) and VLEM were the only mucosal abnormalities in 41 endoscopies (Group 2). Histology was normal in 92 of 160 biopsies (57.5%) from Group 1, and 1 of 41 biopsies (2.4%) from Group 2. Most patients in Group 2 had eosinophilic esophagitis (34 of 41, 83%, specificity 0.85, sensitivity 0.5, p > 0.001) which was of moderate to severe intensity (31 of 34, 91.2%, specificity 0.88, sensitivity 0.73, p < 0.001).
CONCLUSIONS: Histology usually demonstrated moderate to severe inflammation when VLEM were present. VLEM may be a highly specific endoscopic feature of esophagitis in children.

Entities:  

Mesh:

Year:  1997        PMID: 9199905     DOI: 10.1016/s0016-5107(97)70178-0

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  17 in total

Review 1.  GERD in the pediatric patient: management considerations.

Authors:  David A Gremse
Journal:  MedGenMed       Date:  2004-05-05

Review 2.  Allergic eosinophilic esophagitis.

Authors:  Kevin C Bax; Sandeep K Gupta
Journal:  Indian J Pediatr       Date:  2006-10       Impact factor: 1.967

3.  A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease.

Authors:  Evan S Dellon; Hannah P Kim; Sarah L W Sperry; David A Rybnicek; John T Woosley; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2013-11-23       Impact factor: 9.427

Review 4.  Eosinophilic esophagitis: a newly established cause of dysphagia.

Authors:  Brian-M Yan; Eldon-A Shaffer
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

Review 5.  Diagnostics of eosinophilic esophagitis: clinical, endoscopic, and histologic pitfalls.

Authors:  Evan S Dellon
Journal:  Dig Dis       Date:  2014-02-28       Impact factor: 2.404

6.  Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis.

Authors:  T M Runge; S Eluri; J T Woosley; N J Shaheen; E S Dellon
Journal:  Dis Esophagus       Date:  2017-07-01       Impact factor: 3.429

7.  Eosinophilic esophagitis: strictures, impactions, dysphagia.

Authors:  Seema Khan; Susan R Orenstein; Carlo Di Lorenzo; Samuel A Kocoshis; Philip E Putnam; Luther Sigurdsson; Theresa M Shalaby
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

8.  The potential impact of contemporary developments in the management of patients with gastroesophageal reflux disease undergoing an initial gastroscopy.

Authors:  Suhail B Salem; Yael Kushner; Victoria Marcus; Serge Mayrand; Carlos A Fallone; Alan N Barkun
Journal:  Can J Gastroenterol       Date:  2009-02       Impact factor: 3.522

9.  Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study.

Authors:  Vasundhara Tolia; Nader N Youssef; Mark A Gilger; Barry Traxler; Marta Illueca
Journal:  BMC Pediatr       Date:  2010-06-11       Impact factor: 2.125

Review 10.  Eosinophilic esophagitis: the newest esophageal inflammatory disease.

Authors:  Dan Atkins; Robert Kramer; Kelley Capocelli; Mark Lovell; Glenn T Furuta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.